DelphX Announces Warrant Extension
DelphX (OTCQB: DPXCF) intends to seek TSX Venture Exchange approval to extend the exercise period of 3,483,668 share purchase warrants issued Nov 1, 2023, exercisable at $0.20 per common share.
The proposed amendment would extend the warrants by one year to November 1, 2026; all other terms remain unchanged and the extension is subject to TSXV acceptance.
The company disclosed 866,667 warrants are held by related parties and classified the amendment as a related party transaction under MI 61-101 and TSXV Policy 5.9, while noting exemptions apply because the warrants' fair market value does not exceed 25% of market capitalization.
DelphX (OTCQB: DPXCF) intende ottenere l'approvazione della TSX Venture Exchange per estendere il periodo di esercizio di 3.483.668 warrant di acquisto azioni emessi il 1 novembre 2023, exercitabili a $0.20 per azione ordinaria.
La modifica proposta estenderebbe i warrant di un anno fino al 1 novembre 2026; tutti gli altri termini rimangono invariati e l'estensione è soggetta all'accettazione da parte della TSXV.
La società ha comunicato che 866.667 warrant sono detenuti da parti correlate e ha classificato la modifica come una transazione con parti correlate ai sensi di MI 61-101 e della TSXV Policy 5.9, osservando che sono previste esenzioni perché il valore equo di mercato dei warrant non supera il 25% della capitalizzazione di mercato.
DelphX (OTCQB: DPXCF) pretende buscar la aprobación de la TSX Venture Exchange para ampliar el periodo de ejercicio de 3,483,668 warrants de compra de acciones emitidos el 1 de noviembre de 2023, exercitables a $0.20 por acción común.
La enmienda propuesta ampliaría los warrants por un año hasta el 1 de noviembre de 2026; todos los demás términos permanecen sin cambios y la extensión está sujeta a la aceptación por TSXV.
La empresa informó que 866,667 warrants son tenidos por partes relacionadas y clasificó la enmienda como una transacción con partes relacionadas bajo MI 61-101 y la TSXV Policy 5.9, al tiempo que señalan que se aplican exenciones porque el valor razonable de los warrants no excede el 25% de la capitalización de mercado.
DelphX (OTCQB: DPXCF) 는 TSX Venture Exchange 의 승인을 받아 2023년 11월 1일 발행된 3,483,668주의 주식매수워런트의 행사 기간을 연장하려고 합니다, 행사가격은 $0.20 per 보통주입니다.
제안된 수정은 워런트를 1년 연장하여 2026년 11월 1일까지로 하고, 나머지 조건은 변경 없이 유지되며 연장은 TSXV의 승인을 조건으로 합니다.
회사 측은 866,667 워런트가 관련 당사자에 의해 보유되고 있으며 MI 61-101 및 TSXV 정책 5.9에 따라 이를 관련자 거래로 분류했으며, 워런트의 공정가치가 시가총액의 25%를 초과하지 않으므로 면제 적용이 있음을 언급했습니다.
DelphX (OTCQB: DPXCF) envisage d'obtenir l'approbation de la TSX Venture Exchange pour prolonger la période d'exercice de 3,483,668 warrants d'achat d'actions émis le 1er novembre 2023, exerçables à $0,20 par action ordinaire.
La modification proposée étendrait les warrants d'un an jusqu'au 1er novembre 2026 ; toutes les autres conditions restent inchangées et l'extension est soumise à l'acceptation par TSXV.
La société a indiqué que 866,667 warrants sont détenus par des parties liées et a classé la modification comme une opération avec des parties liées en vertu de MI 61-101 et de la Politique TSXV 5.9, tout en indiquant que des exemptions s'appliquent car la juste valeur marchande des warrants ne dépasse pas 25% de la capitalisation boursière.
DelphX (OTCQB: DPXCF) beabsichtigt, die Genehmigung der TSX Venture Exchange zu beantragen, um die Ausübungsfrist von 3.483.668 Aktienkauf-Warrants aus dem 1. November 2023 zu verlängern, die zu $0,20 pro Stammaktie ausübbar sind.
Der vorgeschlagene Änderung würde die Warrants um ein Jahr bis zum 1. November 2026 verlängern; alle anderen Bedingungen bleiben unverändert, und die Verlängerung bedarf der Zustimmung des TSXV.
Das Unternehmen gab bekannt, dass 866.667 Warrants von verbundenen Parteien gehalten werden und die Änderung als Transaktion mit verbundenen Parteien gemäß MI 61-101 und TSXV Policy 5.9 eingestuft wurde, während erklärt wurde, dass Ausnahmen gelten, weil der faire Marktwert der Warrants 25% der Marktkapitalisierung nicht überschreitet.
تخطط DelphX (OTCQB: DPXCF) للحصول على موافقة TSX Venture Exchange لتمديد فترة exerciser لـ 3,483,668 من أذون شراء الأسهم والتي صدرت في 1 نوفمبر 2023، قابلة للتنفيذ عند $0.20 للسهم العادي.
التعديل المقترح سيمدد الأذونات بسنة حتى 1 نوفمبر 2026؛ تبقى جميع الشروط الأخرى دون تغيير، ويرتبط التمديد بقبول TSXV.
أعلنت الشركة أن 866,667 أداة Warrants مملوكة من قبل أطراف ذات صلة وصنفت التعديل كصفقة مع طرف ذو صلة وفق MI 61-101 وسياسة TSXV 5.9، مع الإشارة إلى أن الاستثناءات تنطبق لأن القيمة العادلة للأذونات لا تتجاوز 25% من رأس المال السوقي.
DelphX (OTCQB: DPXCF) 计划寻求 TSX Venture Exchange 的批准，将于2023年11月1日发行的 3,483,668 份认股权证的行权期延长至 $0.20 每股普通股。
拟议的修订将把认股权证延长一年至 2026年11月1日；其他条款保持不变，延长期需经 TSXV 接受。
公司披露有 866,667 份认股权证由相关方持有，并将该修订归类为MI 61-101和TSXV Policy 5.9下的相关方交易，同时指出因认股权证的公允市场价值不超过 市值的25%，适用豁免。
- Warrant exercise period extended to Nov 1, 2026
- Exemptions relied on since warrants' fair market value ≤ 25% of market capitalization
- 3,483,668 warrants outstanding exercisable at $0.20 may increase share count if exercised
- 866,667 warrants held by related parties create a related party transaction requiring TSXV review
Toronto, Ontario--(Newsfile Corp. - October 15, 2025) - DelphX Capital Markets Inc. (TSXV: DELX) (OTCQB: DPXCF) ("DelphX"), a leader in the development of new classes of structured products, announces that it intends to seek approval of the TSX Venture Exchange to extend the exercise period of share purchase warrants.
DelphX intends to seek approval of the TSX Venture Exchange to extend the exercise period of 3,483,668 share purchase warrants, exercisable at
All other terms and conditions of the warrants will remain unchanged. The warrant extension is subject to acceptance by the TSX Venture Exchange.
A total of 866,667 warrants are held by parties who are considered to be "related parties" of DelphX Therefore, the amendment of Warrants constitutes a "related party transaction" as contemplated by Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions, and TSXV Policy 5.9 - Protection of Minority Security Holders in Special Transactions. However, the exemptions from formal valuation and minority approval requirements provided for can be relied upon as the fair market value of the Warrants does not exceed
About DelphX Capital Markets Inc.
DelphX is a technology and financial services company focused on developing and distributing the next generation of structured products. Through its special purpose vehicle Quantem LLC, the Company enables broker dealers to offer new private placement securities that provide for both fixed income and cryptocurrency solutions. The new DelphX securities will enable dealers and their qualified institutional investors (QIBs) accounts to competitively structure, sell and make markets in:
- Collateralized put options (CPOs) that provide secured rating downgrade protection for underlying corporate bonds and/or protection from losses in cryptocurrency holdings;
- Collateralized reference notes (CRNs) that enable investors to take on a capped rating downgrade and/or cryptocurrency loss exposure of an underlying security or cryptocurrency in exchange for attractive returns.
All CPOs and CRNs are fully collateralized and held in custody by US Bank. CPOs and CRNs are proprietary products created and owned by DelphX Capital Markets.
For more information about DelphX, please visit www.delphx.com.
George Wentworth, General Manager
DelphX Capital Markets Inc.
george.wentworth@delphx.com
(718) 509-2160
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/270597
FAQ
What change did DelphX (DPXCF) announce on October 15, 2025?
How many DelphX warrants are exercisable and at what price (DPXCF)?
When would the extended DelphX warrants (DPXCF) expire if approved?
Do related parties hold any DelphX warrants (DPXCF)?
Will the DelphX warrant amendment require shareholder valuation or minority approval?
